 Jubilant Radiopharma, a business unit of Jubilant Pharma Limited and Navidea Biopharmaceuticals, Inc. NYSE MKT: NAVB announced today that both companies have signed a binding memorandum of understanding MOU. The MOU outlines the terms and framework for an Exclusive License and Distribution Agreement ELDA for Navideas diagnostic imaging agent Tilmanocept technetium Tc 99m tilmanocept injection in the United States, Canada, Mexico, and Latin America. In connection with the MOU, Jubilant Radiopharma also made a 1 million equity investment in exchange for a limited exclusivity period while final due diligence efforts are completed. 